Establishment Labs Announces the Appointment of Renee Gaeta as Chief Financial Officer

July 12, 2017

NEW YORK, July 12, 2017 (GLOBE NEWSWIRE)

Establishment Labs, a global medical device company focused on aesthetic technologies with a strong emphasis on product development and innovation announced today that Renee Gaeta has been appointed Chief Financial Officer, effective immediately.

“We are delighted to welcome Renee to our team. Her impressive background in finance and complex transaction management, including the past three years in the aesthetics market, made her an ideal candidate for this key position in our organization,” said Juan José Chacón-Quirós, CEO and founder of Establishment Labs. “I am confident in Renee’s ability to guide and implement our financial strategy and high-growth initiatives as we move towards becoming a global leader in the aesthetic space.”

Ms. Gaeta brings more than a decade of financial leadership experience to Establishment Labs. She recently served as Vice President, Corporate Controller at Sientra, Inc., a Nasdaq listed (SIEN) aesthetics company. At Sientra, she served as a member of the executive team and headed the finance department. She was instrumental in preparing the company during its pre-IPO stage establishing compliant systems and controls, and played a key role in Sientra’s successful Initial Public Offering (IPO) and Follow-On Offering. Prior to Sientra, Ms. Gaeta spent ten years with KPMG, LLP, rising through the organization to the role of Director, Transaction & Restructuring. In this capacity, she managed multiple global clients and specialized in complex transaction and restructuring deals with a focus on evaluation and application of technical accounting.

“I am excited to join a team full of passionate and dedicated individuals who take pride in the design and delivery of high performance aesthetic products to patients,” said Ms. Gaeta. “I look forward to contributing my expertise to the leadership team of Establishment Labs and advance the company’s vision to expand the Motiva Brand and drive long-term growth and value.”

Ms. Gaeta holds a Bachelor of Science in Accounting from Loyola Marymount University and is a Certified Public Accountant in the State of California.

About Establishment Labs
Establishment Labs is a global, privately held, medical technology company with a strong emphasis on innovation that designs, develops, manufactures and markets an innovative product portfolio. Its CE-marked Motiva Implants® line of silicone breast implants (http://www.motivaimplants.com) utilizes ultra-high purity medical-grade silicone and is subject to the strictest quality assurance testing throughout the manufacturing process. Motiva Implants® are sold in more than 60 countries worldwide. Puregraft®’s FDA cleared and CE-Marked technology provides plastic surgeons with purified fat for reinjection on the sterile field and is used in hospitals and clinics around the world. Divina® is a proprietary 3D imaging technology for full integration in consultation and surgical planning of unique solutions for breast aesthetics and reconstruction. All manufacturing facilities are fully compliant with both FDA and ISO applicable standards.